Resmed and Koninklijke Philips NV face market challenges due to reduced need for sleep apnea treatments, coupled with a competitor re-entering the U.S. market.
3 reports, 3 independent
Updated Sep 19
Gone quiet
- Reports
- 3
- Developments
- 2
- Repetition
- 33%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Resmed and Koninklijke Philips NV face market challenges due to reduced need for sleep apnea treatments, coupled with a competitor re-entering the U.S. market.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.RBC Capital Markets upgraded ratings amid rivalry in the sleep apnea market between Resmed and Philips.1 source
Market headwinds hit Resmed and Philips amid GLP-1 trends and competitor return.1 source
Keep exploring
The entities involved
-
Resmed
manufacturer of CPAP masks, machines and products that diagnose, treat or help manage respiratory conditions
Nothing else this week.
-
Morgan Stanley
U.S. investment bank
- Multiple financial institutions, including Goldman Sachs, Morgan Stanley, Bank of America, UBS, and others, provided ratings and price targets for Marvell Technology on May 28, 2026.
- Goldman Sachs and Morgan Stanley noted that semiconductor stocks benefit from current rate levels but face market caution.
-
Koninklijke Philips NV
Dutch multinational conglomerate corporation